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Abstract
Introduction Multifocal motor neuropathy (MMN) is char-
acterized by asymmetric weakness of limbs and the
electrophysiological finding of conduction block in motor
nerves. Conduction block is the inability of nerves to
propagate action potentials and is probably caused by
immune-mediated dysfunction of the axon at the nodes of
Ranvier or the myelin sheath. MMN immune pathogenesis
has not been elucidated.
Results In approximately 50% of all patients, IgM anti-
bodies that bind to the glycolipid GM1, which is abun-
dantly expressed in peripheral motor nerves, can be
detected. A recent study showed an association with
HLA-DRB1*15, and virtually all patients respond to
treatment with intravenous immunoglobulin (IVIG) in at
least the early stages of the disease.
Conclusion This review aims at providing a concise
overview of what is known about MMN pathogenesis,
and how the beneficial effect of IVIG might be explained.
Keywords Multifocal motor neuropathy.intravenous
immunoglobulin.conduction block.GM1 antibodies
Clinical Picture of MMN
Asymmetric weakness of distal arm muscles without
sensory deficits is a highly uncommon presentation for a
peripheral neuropathy. Until its first detailed description in
1988 [1], multifocal motor neuropathy (MMN) was often
diagnosed as amyotrophic lateral sclerosis (ALS) with a
surprisingly benign disease course. ALS is a neurodegen-
erative disorder caused by degeneration of motor neurons in
the anterior horn of the spinal cord and upper motor
neurons in the central nervous system (CNS). Unlike ALS,
which has a poor prognosis with a median survival of
approximately 3 years, patients with MMN have a normal
life expectancy, with gradual or stepwise progressive
weakness of muscles in the distal arm and leg or a stable
disease course after onset [2, 3].
Conduction block (CB) is the characteristic hallmark that
distinguishes MMN from ALS and other disorders with a
comparable clinical phenotype [1–3]. CB is defined as an
inability of motor nerves to propagate action potentials
during nerve conduction studies. Although there are many
definitions of CB, we define probable CB as a 30-50%
reduction of the area of the compound muscle action
potential (CMAP) in the arms or >50% reduction in the
legs. Definite CB is defined as a >50% reduction of CMAP
area in the arms. In the absence of CB, a diagnosis of
(possible) MMN can be made if nerve conduction studies
show signs of demyelination in combination with the
presence of anti-GM1 IgM antibodies in serum and
abnormal magnetic resonance imaging of the brachial
plexus [3]. The diagnostic criteria for MMN are summa-
rized in Table I.
Conduction Block and Nerve Pathology
The underlying mechanisms of nerve dysfunction and, in
particular, CB in patients with MMN are incompletely
understood. CB could be caused by dysfunction of the axon
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motor nerves are equivocal, showing both signs of
demyelination [4] and axonal degeneration [5]. Electro-
physiological studies have confirmed that axonal degener-
ation is common in MMN [6, 7] and that it is the most
important determinant of permanent weakness [7].
Nerve excitability studies have been used to address
whether CB is caused by depolarizing or hyperpolarizing
mechanisms but have yielded inconsistent results. Hyper-
polarization, depolarization, and combinations have been
described [6, 8]. Depolarizing CB may precede hyper-
polarizing CB in the course of MMN, but these findings
remain to be confirmed [8]. Importantly, axonal dysfunction
in MMN may be more widespread than solely at the site of
CB; this is possibly due to Na
+ channel dysfunction [9].
Axonal dysfunction decreased after treatment with IVIG,
which suggest underlying immune-mediated mechanisms.
A groundbreaking experimental study using a rabbit model
for acute motor axonal neuropathy (AMAN) has provided
important insight into how antibodies against GM1 disrupt
the architecture of Na
+ channel clusters at the nodes of
Ranvier [10]. By analogy, this study has offered important
clues as to how immunological and electrophysiological
features of MMN are linked.
Anti-Ganglioside Antibodies and MMN
The presence of serum IgM antibodies against GM1 was
acknowledged in the first description of MMN [1] and has
Table I Proposed Diagnostic Criteria for MMN
Clinical criteria
1. Slow or stepwise progressive limb weakness
2. Asymmetrical limb weakness
3. Fewer than 7 affected limb regions (upper/lower arm, upper/lower leg on both sides, maximum 8)
4. Tendon reflexes in affected limbs are decreased or absent
5. Signs and symptoms are more pronounced in arms than in legs
6. Age 20-65 years at onset of disease
7. No objective sensory abnormalities except for vibration sense
8. No bulbar signs or symptoms
9. No upper motor neuron features
10. No other neuropathies
Laboratory criteria
1. CSF protein <1 g/L
2. High anti-GM1 IgM titer
3. High signal intensity on T2-weighted MRI of the brachial plexus
Electrodiagnostic criteria
1. Definite motor conduction block: CMAP area reduction on proximal versus distal stimulation of at least 50% over a long segment (between
erb and axilla, upper arm, lower arm, lower leg), or a CMAP amplitude reduction on proximal versus distal stimulation of at least 30% over a
short distance (2.5 cm) detected by inching. CMAP amplitude on stimulation of the distal part of the segment with motor conduction block of
at least 1 mV
2. Probable motor conduction block: CMAP amplitude reduction on proximal versus distal stimulation of at least 30% over a long segment of an
arm nerve. CMAP amplitude on stimulation of the distal part of the segment with motor conduction block of at least 1 mV
3. Slowing of conduction compatible with demyelination: MCV 75% of the lower limit of normal; DML or shortest F wave latency 130% of the
upper limit of normal or absence of F waves all after 16-20 stimuli. CMAP amplitude on distal stimulation of at least 0.5 mV
4. Normal sensory nerve conduction in arm segments with motor conduction block. Normal SNAP amplitudes on distal stimulation
Definite MMN
1-11 on clinical criteria, 1 on laboratory criteria, 1 and 4 on electrodiagnostic criteria
Probable MMN
1-3 and 6-11 on clinical criteria, 1 on laboratory criteria, 2 and 4 on electrodiagnostic criteria
Possible MMN
1 and 7-11 on clinical criteria, 2 or 3 on laboratory criteria, 3 and 4 on electrodiagnostic criteria
CSF cerebrospinal fluid, MRI magnetic resonance imaging, CMAP compound muscle action potential, MCV motor conduction velocity, DML
distal motor latency, SNAP sensory nerve action potential
Adapted from: Van Asseldonk JT, Franssen H, Van den Berg-Vos RM, Wokke JH, van den Berg LH: Multifocal motor neuropathy. Lancet Neurol.
4:309-319, 2005
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reported prevalence of IgM antibodies against GM1 in
MMN patients varies widely, probably due to differences
in laboratory assays [2, 3], these antibodies can be detected
in serum samples from approximately half of all MMN
patients. GM1 is a glycolipid from the family of ganglio-
sides, which consist of a ceramide anchor coupled to a
varying number of oligosaccharide residues and sialic acids
[11].
Although gangliosides are abundantly expressed in
nervous tissues, their biological functions are not complete-
ly understood. From the 1980s, it is becoming increasingly
clear that gangliosides are important targets for antibodies
in immune-mediated neuropathies, in particular AMAN, the
extensively studied pure motor axonal variant of Guillain-
Barré syndrome (GBS). The gangliosides GM1 and GD1a
are especially abundant in motor nerves, and antibodies
from all major isotypes (IgM, IgG, IgA) against these
gangliosides are detected in serum from AMAN patients.
These antibodies are elicited by infection with micro-
organisms expressing ganglioside-like mimics on their
surface (a process called molecular mimicry) a few days
or weeks prior to disease onset [11]. Similarly, experimental
exposure to gangliosides or bacterial constituents exposing
ganglioside-like structures induces inflammatory neuropa-
thy in rabbits and humans [11]. Anti-ganglioside IgG
antibodies were shown to induce inflammation and to
disrupt nerve function by activating complement and
leukocytes after binding to their targets [12].
The pathogenic role of anti-ganglioside IgM antibodies
in MMN is less clear. Some have questioned the validity of
analogy in MMN, pointing at the exclusive presence of the
IgM isotype, the absence of these antibodies in sera from
more than half of the patients with MMN, and the fact that
anti-GM1 IgM antibodies are occasionally also detected in
sera from patients with motor neuron disease [2]. Never-
theless, anti-GM1 IgM antibodies in sera from both GBS
and MMN patients have been shown to activate comple-
ment [13]. Complement activation after binding to ganglio-
sides is an essential step in all available models of
anti-ganglioside-mediated neuropathy. The deposition of
complement factors caused dysfunction of the neuromus-
cular junction in a mouse model [12] and induced changes
in the architecture of the nodes of Ranvier and paranodal
junctions, which resulted in disruption of Na
+ channel
clusters in the rabbit model of AMAN [10]. Importantly,
complement-inhibiting drugs adequately counteracted these
pathogenic effects [12, 14]. These studies suggest that
antibody-complement interactions are a common final
pathway in the pathogenesis of MMN and AMAN. The
exclusive presence of the IgM isotype in serum from MMN
patients, which generally has lower binding affinity for
GM1 and reduced access through the blood-nerve barrier
due to its larger size in comparison with IgG, may explain
the differences in severity of weakness between patients
with MMN and AMAN. The supposed key players in
MMN pathogenesis are depicted in Fig. 1.
Origin of Anti-GM1 IgM Antibodies in MMN Patients
The presence of anti-GM1 IgM antibodies in serum from
almost 50% of patients with MMN seems to suggest an
activation of GM1-specific B cells. Assuming that these
antibodies contribute to the etiopathogenesis of MMN and
are not secondary to the release of gangliosides from
damaged axons, elucidation of the mechanism of GM1-
specific B-cell activation may provide clues for alternative
treatment strategies. GM1-specific B cells may be activated
by infections (molecular mimicry), intrinsic B-cell clone
changes (monoclonal gammopathy), or by autoimmune
mechanisms.
The almost exclusive presence of IgM and the results
from serological studies, which indicate that few MMN
patients had infections with the GM1-mimic expressing
Campylobacter jejuni [15], do not support pathogenic
similarities with AMAN. The hypothesis that MMN is a
postinfectious or parainfectious disorder may be hard to
investigate. The chronic disease course in MMN may cause
bias in recall of individual infectious histories, and
maintenance treatment with IVIG complicates the interpre-
tation of serological studies; thus, excluding methodology
that has been pivotal in the dissection of GBS pathogenesis
[11]. Although monoclonal gammopathy has been observed
in patients with MMN, it cannot be detected by immuno-
fixation in the large majority of patients [2, 3]. Monoclonal
gammopathy of GM1-specific B cells does not, therefore,
offer a satisfactory explanation for MMN in the majority of
patients.
It is not clear also whether MMN is a classic
autoimmune disease. Although the overrepresentation of
male patients may argue against autoimmune disease, we
observed a clear association of MMN with the HLA-
DRB1*15 allele in a case-control study of 74 patients with
MMN and 700 controls. Interestingly, this association is
also reproducibly found in patients with multiple sclerosis,
a multifocal demyelinating disease of the CNS [16]. This
association may suggest pathogenic similarities with mul-
tiple sclerosis and provide a new clue for MMN pathogen-
esis, i.e., a contribution of antigen-presenting cells (APC).
APC are pivotal in triggering adaptive immune responses
by presenting autoantigens to T cells or B cells. Glycolipids
are not presented by APC in an HLA-restricted fashion but
by HLA-like molecules from the CD1 family. Polymor-
phisms of CD1 molecules were not found to be associated
with MMN [17]. The association with HLA-DRB1*15 was
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This may, therefore, suggest the existence of as yet
unidentified autoantigens or indicate the presence of genetic
risk factors that are in linkage disequilibrium with the
HLA-DRB1*15 allele.
The latter possibility may be supported by the lack of
evidence for T-cell involvement in MMN. Lymphocytic
infiltrates were absent [4] or minute [5] in pathological
studies, and serological studies have failed to show
increased levels of T-cell activating interleukins (IL) such
as IL-2 [18]. This is compatible with the notion that
glycolipids are T-cell independent antigens and that B cells
are the major culprits in the majority of immune-mediated
polyneuropathies including MMN.
Treatment of MMN: Present and Future
Treatment trials have uncovered a unique pattern of
responsiveness to immune modulatory treatment in MMN.
Treatment with IVIG has been shown to be beneficial in
randomized controlled trials. Cyclophosphamide has been
reported to be effective, but its toxicity precludes long-term
use, which is usually necessary in patients with MMN.
Plasma exchange and prednisone are well-established
therapies in other immune-mediated neuropathies, but have
not been shown to be effective in patients with MMN and
may even aggravate symptoms [2, 3]. This pattern supports
the crucial role of B cells, antibodies, and complement in
MMN pathogenesis. Cyclophosphamide is an efficient B-
cell inhibiting drug. IVIG may have multiple effects on the
humoral part of the immune system of MMN patients,
which all contribute to its beneficial effect [19]. First, IVIG
may exert anti-idiotypic effects that reduce levels of
circulating anti-GM1 IgM antibodies and interfere with B-
cell receptors on GM1-specific clones. Second, IVIG may
induce inhibitory receptors on B cells as has been shown in
patients with chronic inflammatory demyelinating poly-
neuropathy [20]. Finally, IVIG may interfere with anti-
GM1 IgM-mediated complement deposition in nerves [19].
Despite IVIG effectiveness, most patients with MMN
experience mild progression of weakness during IVIG
maintenance treatment of many years, which can be











Fig. 1 Schematic depiction of assumed key players in MMN
pathogenesis. Anti-GM1 IgM and possibly other antibodies are
produced by B cells that may be specifically activated by antigen
presenting cells (APC), or through “bystander” effects. There are no
indications that T cells are involved. These IgM antibodies may bind
to GM1 in nerves if the blood-nerve barrier is leaky, and may locally
activate complement. The deposition of complement disrupts the
architectural integrity of the nodes of Ranvier and paranodal regions,
causing local disruption of Na
+ channel clusters. This may ultimately
contribute to axonal depolarization or hyperpolarization and conduc-
tion block. IVIG might interfere with B-cell antibody production
through binding to the B-cell receptor or inducing inhibitory receptors,
with anti-GM1 antibodies through anti-idiotypic effects, or it might
attenuate complement deposition
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postpone the occurrence of permanent axonal damage [7], it
is not known which dose and treatment would be optimal.
In addition to studies that would optimize IVIG treatment
strategies for patients with MMN, experimental studies
suggest that add-on therapy with B-cell and complement-
specific agents might be successful. Anecdotal reports of
the long-lasting effects of B cell-specific anti-CD20
monoclonal antibodies (rituximab) call for a randomized
trial. Specific inhibitors of the complement system may
represent alternative candidates [12, 14], because they
might prevent permanent axonal damage. But they also
may increase the risk of severe bacterial infections.
Conclusion
MMN is a rare immune-mediated neuropathy that responds
to IVIG therapy. Although its pathogenesis is not com-
pletely understood, the available data strongly suggest a
role for B cells, IgM antibodies, and complement. Further
dissection of its etiology may help to select effective
treatment modalities. Future treatment strategies should
aim ultimately at preventing permanent axonal damage
without increasing the risk of serious side effects.
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